Cartherics is a private Melbourne-based biotechnology company, focused on developing cutting edge technologies to empower the immune system to specifically target and ultimately eliminate cancer. The focus technology is Chimeric Antigen Receptors for T cells (CAR-T) and NK cells (CAR-NK). The Cartherics business model is distinguished by the development of novel single or dual specific CAR-T/NK cells targeting strategically chosen cancer antigens coupled to editing out of genes that compromise killing function. The key antigen is broadly expressed by adenocarcinomas, and cutaneous T cell lymphoma but is virtually absent in normal tissue. The primary goal of the company is to develop “off the shelf” allogeneic CAR-NK and CAR-T cells differentiated from iPSC derived from homozygous HLA haplotype donors, using viral-free transduction to genetically sculpture the iPSC. Genetically modified single specificity CAR-T cells are planned for near term autologous Phase I clinical trial(s). Cartherics hold patent applications for its key platforms.

Contact Cartherics Pty Ltd
Visit Website